Cost-effectiveness analysis of budesonide/formoterol maintenance and reliever therapy versus fixed combination treatments for asthma in Finland

Current Medical Research and Opinion

Volumn 24, Issue 12, 2008, Pages 3453-3461

  Tamminen, Klaus ^a   Laine, Juha ^a   Soini, Erkki ^b   Martikainen, Janne ^b   Kankaanranta, Hannu ^c,d  

^a ASTRAZENECA   (United Kingdom)

^b Esior Oy   (Finland)

^c SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Asthma; Budesonide formoterol maintenance and reliever therapy; Cost effectiveness; Salmeterol fluticasone

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; PREDNISOLONE; TERBUTALINE; BRONCHODILATING AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADULT; ASTHMA; BOOTSTRAPPING; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FINLAND; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; PROBABILITY; RISK REDUCTION; ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; ECONOMICS; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FINLAND; HUMANS; MALE; MIDDLE AGED;

EID: 62349118812     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802567566     Document Type: Conference Paper

References (35)

1. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-722 (Pubitemid 29401332)
2. National Agency for Medicines and Finnish Social Insurance Institution: Finnish Statistics on Medicines 2006. Helsinki
3. Haahtela T, Tuomisto L, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;61:663-670 (Pubitemid 44211772)
4. Hallinen T, Karjalainen J, Hahl J, et al. Reduction in total treatment costs through improved pharmaceutical treatment of obstructive airway diseases. Value Health 2007;10:A308
5. Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-392
6. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, Revised 2006. www.ginasthma.org
7. Kankaanranta H, Lahdensuo A, Moilanen E, et al. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res 2004;5:17 (Pubitemid 41363578)
8. Ikaheimo P, Tuuponen T, Hartikainen S, et al. Achievements and shortcomings of Finnish asthma care. Scand J Public Health 2004;32:310-316
9. Rabe K, Vermeire P, Soriano J, et al. Clinical management of asthma in 1999: the Asthma Insights in Europe (AIRE) study. Eur Respir J 2000;16:802-807
10. Firoozi F, Lemiere C, Beauchesne M-F, et al. Development and validation of database indexes of asthma severity and control. Thorax 2007;62:581-587 (Pubitemid 47056883)
11. O'Byrne P, Bisgaard H, Godard P, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-136 (Pubitemid 40105411)
12. Barnes, P. Scientific rationale for using a single inhaler for asthma control. Eur Resp J 2007;29:587-595 (Pubitemid 46372109)
13. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004;20:1403-1418 (Pubitemid 39361344)
14. Rabe K, Pizzichini B, Stallberg S, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006;129:246-256 (Pubitemid 43289841)
15. Rabe K, Pizzichini E, Ställberg B, et al. Effect of budesonide in combination with formoterol for reliever medication on asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-753 (Pubitemid 44279053)
16. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-828
17. Miller E, FitzGerald M. Budesonide/formoterol as maintenance and reliever treatment compared to fixed dose combination strategies - a Canadian economic evaluation. Can J Clin Pharmacol 2008;15:e165-76 (Pubitemid 351838504)
18. Johansson G, Andreasson E, Larsson P, et al. Cost Effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmacoeconomics 2006;24:695-708 (Pubitemid 43998822)
19. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:1189-1198 (Pubitemid 47374022)
20. Rissanen P, Häkkinen U. Priority-setting in Finnish healthcare. Health Policy 1999;50:143-153 (Pubitemid 30038211)
21. Häkkinen U, Lehto J. Reform, change, and continuity in Finnish health care. J Health Polit Pol Law 2005;30:79-96 (Pubitemid 40627007)
22. Martikainen J, Kivi I, Linnosmaa I. European prices of newly launched reimbursable pharmaceuticals - a pilot study. Health Policy 2005;74:235-246 (Pubitemid 41446131)
23. O'Sullivan A, Thompson D, Drummond M. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations? Value Health 2005;8:67-79
24. Kuna P, Peters M, Manjra A, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:35-36 (Pubitemid 46587876)
25. Hujanen T, Kapiainen S, Tuominen U. Terveydenhuollon yksikkö kustannukset Suomessa vuonna 2006. Työpapereita 3. Helsinki: Stakes
26. VSSHP Price list. The Hospital District of Southwest Finland 2006
27. TAKSA database of the Association of Finnish Pharmacies for August 2008
28. Cook J, Drummond M, Glick H, et al. Assessing the appropriateness of combining economic data from multinational clinical trials. Statist Med 2003;22:1955-1976 (Pubitemid 36758398)
29. Briggs A. Handling uncertainty in economic evaluation and presenting the results. In: Drummond M, McGuire A, eds. Economic Evaluation in Health Care - Merging Theory with Practice. Oxford: Oxford University Press/Office of Health Economics, 2001:172-214
30. Briggs A, Wonderling D, Mooney C. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-340 (Pubitemid 27384638)
31. Keränen J, Soini E, Ryynänen O, et al. Economic evaluation comparing From Home To Operation same day admission and preoperative admission 1 day prior to the surgery process: a randomized controlled trial of laparoscopic cholecystectomy. Curr Med Res Opin 2007;23:775-784 (Pubitemid 350146415)
32. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-787 (Pubitemid 34041389)
33. Helin-Salmivaara A, Mäkinen R, Haahtela T. Uusien astmapotilaiden lääkehoito vaihtelee alueittain suuresti. Suom Lääkäril 2005;8:920-922
34. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994;3:95-104
35. O'Brien B. 1996. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 1996;34:S33-40